Colorectal Cancer: From Genetic Landscape to Targeted Therapy

Table 2

mAbs targeting EGFR pathway under clinical investigation.

Drugs	Target	Setting	Treatment	Phase	Identifiers
Trastuzumab	HER2	HER2-positive wild KRAS mCRC	Trastuzumab + Lapatinib or Pertuzumab	II	NCT03225937
			Trastuzumab + Tucatinib		NCT03043313
Pertuzumab	HER2	2nd line of advanced or mCRC	Pertuzumab + cetuximab	I/II	NCT00551421
MEHD7945A (Duligotuzumab)	EGFR/HER3	2nd line K-Ras wild-type mCRC	MEHD7945A + FOLFIRI vs. Cetuximab + FOLFIRI	II	NCT01652482
SYM004	EGFR	mCRC K-Ras WT acquired resistance to Anti-EGFR mAbs	SYM004 vs. BSC	II	NCT02083653
CPGJ 602	EGFR	2nd line mCRC KRAS WT	CPGJ 602 vs. Cetuximab	I	NCT03356158
Futuximab	EGFR	Chemotherapy-refractory mCRC	Futuximab vs. SYM004	II	NCT03549338
SCT 200	EGFR	Wild-type RAS and RAF mCRC	SCT200	II	NCT03405272
Dalotuzumab (MK-0646)	IGF-1R	Wild-type KRAS mCRC	Dalotuzumab + Cetuximab + irinotecan	II/III	NCT00614393
Ganitumab (AMG-479)	IGF-1R	Mutant KRAS mCRC	AMG-479 + FOLFIRI vs. FOLFIRI alone	II	NCT00813605
Cixutumumab (IMC-A12)	IGF-1R	2nd line mCRC kRAS wild-type	Irinotecan and Cetuximab ± IMC-A12	II	NCT00845039

mAbs: monoclonal antibodies; mCRC: metastatic colorectal cancer; FOLFIRI: irinotecan in combination with 5-fluorouracil and folinic acid; BSC: best supportive care; HER: human epidermal growth factor receptor; EGFR: epidermal growth factor receptor; IGF-1R: insulin-like growth factor 1 receptor; KRAS: Kirsten rat sarcoma viral oncogene.